To Study GSP 301 in Patients With Seasonal Allergic Rhinitis
Public ClinicalTrials.gov record NCT02318303. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Randomized, Parallel-group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Two Different Strengths and Regimens of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Comparators), in Subjects (12 Years of Age and Older) With Seasonal Allergic Rhinitis (SAR)
Study identification
- NCT ID
- NCT02318303
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Glenmark Pharmaceuticals Ltd. India
- Industry
- Enrollment
- 1,111 participants
Conditions and interventions
Conditions
Interventions
- GSP 301-1 NS (QD) Drug
- GSP 301-2 NS (BID) Drug
- GSP 301 Placebo NS Drug
- Olopatadine HCl-1 NS (QD) Drug
- Olopatadine HCl-2 NS (BID) Drug
- Mometasone Furoate-1 NS (QD) Drug
- Mometasone Furoate-2 NS (BID) Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2014
- Primary completion
- Jan 31, 2015
- Completion
- Jan 31, 2015
- Last update posted
- Oct 19, 2020
2014 – 2015
United States locations
- U.S. sites
- 10
- U.S. states
- 1
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Glenmark Investigational Site 10 | Austin | Texas | — | — |
| Glenmark Investigational Site 5 | Austin | Texas | — | — |
| Glenmark Investigational Site 6 | Austin | Texas | — | — |
| Glenmark Investigational Site 2 | Kerrville | Texas | — | — |
| Glenmark Investigational Site 7 | New Braunfels | Texas | — | — |
| Glenmark Investigational Site 3 | San Antonio | Texas | — | — |
| Glenmark Investigational Site 4 | San Antonio | Texas | — | — |
| Glenmark Investigational Site 8 | San Antonio | Texas | — | — |
| Glenmark Investigational Site 9 | San Antonio | Texas | — | — |
| Glenmark Investigational Site 1 | Waco | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02318303, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 19, 2020 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02318303 live on ClinicalTrials.gov.